A phase III trial of remetinostat for the treatment of early-stage cutaneous T-cell lymphoma

Trial Profile

A phase III trial of remetinostat for the treatment of early-stage cutaneous T-cell lymphoma

Planning
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Medivir AB
  • Most Recent Events

    • 18 Jun 2018 According to a Medivir AB media release, the company decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the design and start of the study will not be possible earlier than 2019.
    • 14 Feb 2018 According to a Medivir AB media release, discussions with regulatory authorities on the design of this study are underway.
    • 07 Apr 2017 According to a Medivir AB media release, based on the data from Phase II trial (see profile 243325) company is planning to initiate discussions with regulatory authorities with the aim of initiating this trial later in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top